Author

Findlay Bewicke‐Copley

Queen Mary University of LondonORCID 0000-0003-1292-7965Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Assay:metabolomics· 2 Assay:proteomics· 2 Assay:CUT&Tag· 1

Frequent Co-Authors

Pedro R. CutillasiD· 3 shared Alun Parsons· 2 shared Ana Rio‐MachíniD· 2 shared Caroline Akemi HeckmaniD· 2 shared Csaba BödöriD· 2 shared John G. GribbeniD· 2 shared Jude FitzgibboniD· 2 shared Juho Jalmari MiettineniD· 2 shared

Activity by Year

2023-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Pedro R. CutillasORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyLeukemiaPeer-reviewedApr 9, 2025

DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes

Fadimana Kaya, Findlay Bewicke‐Copley, Juho Jalmari Miettinen…·Ana Rio‐Machín

This study identifies DEK::NUP214 as an XPO1-dependent transcriptional activator of leukemia genes, showing selective response to XPO1 inhibitors in t(6;9) AML cases.

10 citationstop 2%

humanwhole-genome sequencing

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 27, 2025

High levels of DNA replication initiation factors indicate ATR inhibitor sensitivity via excessive origin firing

Audrey Lumeau, Pauline Luise Pfuderer, S De Angelis…·Sarah Elizabeth McClelland

This study identifies that high levels of DNA replication initiation factors correlate with ATR inhibitor sensitivity due to excessive origin firing in cancer cells.

1 citation

humanproteomics

𝕏 PostBluesky

Molecular BiologySignal Transduction and Targeted TherapyPeer-reviewedFeb 26, 2023

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes

Pedro Casado, Ana Rio‐Machín, Juho Jalmari Miettinen…·Pedro R. Cutillas

The paper identifies two distinct subgroups of KMT2A-rearranged AML using phosphoproteomics and shows different drug response profiles.

33 citationstop 2%

humanproteomics

𝕏 PostBluesky